Cerevance’s First-In-Class Parkinson’s Candidate Shows Phase II Promise

CEO Predicts Annual Revenues Up To $1bn

 
• By Andrew McConaghie
  
Parkinsons Drugs
The drug candidate could be used in combination with existing Parkinson's treatments, such as levadopa, but must first replicate the results in a larger pivotal study. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip